dr reddy's semaglutide Delhi High Court stops Dr. Reddy's from selling Ozempic-like drug after Novo Nordisk claims patent infringement. For More Details Visit: https://lawchakra.in/high-court/ozempic-drug-india-dr-reddys-novo-nordisk/ #delhihighcourt Dr Reddy's Launches Semaglutide Injection

Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death

The other avenue of research is more clinical trials with GLP-1 RAs plus psoriasis medicines. Additionally, GLP-1 RA therapy is being explored for use in other dermatologic conditions, including hidradenitis suppurativa, acanthosis nigricans, chronic wounds and ulcers, weight-loss-related lipoatrophy, and skin laxity

Thus, the idea of utilising glucagon RAs for metabolic disease would seem counterintuitive, at least in people with diabetes

Source: Polaris Market Research Analysis Regional Analysis The North America semaglutide market accounted for the largest share in 2024

The fact that these benefits extend beyond glycemic control is further supported by the significant subgroup interaction observed for MI, suggesting that nondiabetic and obese patients may derive greater benefit from GLP-1 RA therapy compared with their diabetic or nonobese counterparts